Disease · MONDO_0018666

hepatoblastoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. hepatoblastoma. Diseases, record MONDO_0018666. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018666

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: hepatoblastoma; Open Targets
Open Targets ID: MONDO_0018666; Open Targets
Other names: HBL, hepatoblastoma, malignant, paediatric embryonal hepatoma, paediatric hepatoblastoma, pediatric embryonal hepatoma, pediatric hepatoblastoma; Open Targets
Disease Ontology: DOID:687; Disease Ontology
MeSH: D018197; MeSH
NCI Thesaurus: C3728; NCI Thesaurus
Orphanet: ORPHA:449; Orphanet
Highest stage of its drugs: Phase 3, for 17 of its 34 drugs, from ClinicalTrials.gov; Open Targets

Drugs34

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
IRINOTECAN	CHEMBL481	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
VINCRISTINE SULFATE	CHEMBL501867	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
DOXORUBICIN HYDROCHLORIDE	CHEMBL359744	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
IRINOTECAN HYDROCHLORIDE	CHEMBL3989514	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 34

See all 34 drugs

Targets52

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TOP1	DNA topoisomerase 1	4	DNA topoisomerase I inhibitor	Phase 3	https://conductscience.org/library/genes/7150	Drugs and targets
TOP2A	DNA topoisomerase 2-alpha	4	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Phase 3	https://conductscience.org/library/genes/7153	Drugs and targets
PDCD1	Programmed cell death protein 1	3	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2/3	https://conductscience.org/library/genes/5133	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
KDR	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
TOP2B	DNA topoisomerase II	2	DNA topoisomerase II inhibitor	Phase 3	https://conductscience.org/library/genes/7155	Drugs and targets
TUBA1A	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets

1 to 10 of 52

See all 52 targets

Trials18

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00980460	Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer	Phase 3	236	2021-12-28	PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma, PRETEXT IV Hepatoblastoma	CISPLATIN, DEXRAZOXANE, DOXORUBICIN HYDROCHLORIDE, FLUOROURACIL, IRINOTECAN HYDROCHLORIDE, TEMSIROLIMUS, VINCRISTINE SULFATE	Its record names the disease	ClinicalTrials.gov
NCT01154816	Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia	Phase 2	118	2017-06-05	Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Kidney Neoplasm, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma	ALISERTIB	Its record names the disease	ClinicalTrials.gov
NCT03533582	Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery	Phase 3	537		Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma, Hepatoblastoma, Hepatocellular Malignant Neoplasm, Not Otherwise Specified	CARBOPLATIN, CISPLATIN, DOXORUBICIN, ETOPOSIDE, FLUOROURACIL, GEMCITABINE, IRINOTECAN, OXALIPLATIN, SORAFENIB, VINCRISTINE SULFATE	Its record names the disease	ClinicalTrials.gov
NCT03017326	Paediatric Hepatic International Tumour Trial	Phase 3	450		Hepatoblastoma, Carcinoma, Hepatocellular	CARBOPLATIN, CISPLATIN, DOXORUBICIN, ETOPOSIDE, FLUOROURACIL, GEMCITABINE, IRINOTECAN, OXALIPLATIN, SORAFENIB, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT04478292	A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy	Phase 3	330		Hepatoblastoma	CARBOPLATIN, CISPLATIN, DOXORUBICIN, FLUOROURACIL, IRINOTECAN, SODIUM THIOSULFATE, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT00003994	Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer	Phase 3	277		Childhood Hepatoblastoma, Recurrent Childhood Liver Cancer, Stage I Childhood Liver Cancer	AMIFOSTINE, CARBOPLATIN, CISPLATIN, FLUOROURACIL, VINCRISTINE SULFATE	Its record names the disease	ClinicalTrials.gov
NCT00003912	Chemotherapy in Treating Children With Liver Cancer	Phase 3	260		Liver Cancer	CARBOPLATIN, CISPLATIN, DOXORUBICIN HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT04851119	Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors	Phase 1/2	147		Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma, Ovarian Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Desmoid Fibromatosis, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Refractory Desmoid Fibromatosis, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Solid Pseudopapillary Neoplasm of the Pancreas, Wilms Tumor	TEGAVIVINT	Its record names the disease	ClinicalTrials.gov
NCT00918320	Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours	Phase 2	129		Neuroblastoma, Brain Tumors, Solid Tumors	TEMOZOLOMIDE, TOPOTECAN	Its record names the disease	ClinicalTrials.gov
NCT07300449	A Prospective Multicenter Clinical Study of SCCG Protocol and ctDNA 5hmc in Predicting the Chemotherapy Sensitivity and Monitoring the Recurrence and Metastasis of Hepatoblastoma in Children and Adolescents	Phase 2	100		Hepatoblastoma	CARBOPLATIN, CISPLATIN, DOXORUBICIN, ETOPOSIDE, IFOSFAMIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 18

See all 18 trials

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Intermediate-risk Group (Regimen F) vs High-risk Group (Regimen H): Feasibility of Referral for Liver Transplantation	37 of 57	16 of 31	88	NCT00980460

Source Trial comparisons

Papers from its trials15

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31595663	RESULT	1	PubMed
31160205	RESULT	1	PubMed
29924955	RESULT	1	PubMed
27914822	RESULT	1	PubMed
27884679	RESULT	1	PubMed
23831416	RESULT	2	PubMed
22547603	RESULT	1	PubMed
19846851	RESULT	1	PubMed
9849694	RESULT	1	PubMed
37073741	DERIVED	1	PubMed

1 to 10 of 15

See all 15 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0018666

GET https://conductscience.org/api/diseases/v1/MONDO_0018666/drugs?page=2

API reference For AI assistants